Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures.
It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.
Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | David Hochman |
Contact Details
Address: 150 Union Square Drive New Hope, Pennsylvania 18938 United States | |
| Phone | 215 862 5797 |
| Website | orchestrabiomed.com |
Stock Details
| Ticker Symbol | OBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001814114 |
| CUSIP Number | 68572M106 |
| ISIN Number | US68572M1062 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David P. Hochman | Founder, Chairman of the Board of Directors and Chief Executive Officer |
| Darren R. Sherman | Founder, President, Chief Operating Officer and Director |
| Andrew Lawrence Taylor M.B.A. | Chief Financial Officer |
| William Reed Little | Executive Vice President of Corporate Development and Strategy |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM and Chief Technology Officer of Bioelectronic Therapies |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs and Innovation |
| Bob Laughner | Senior Vice President of Regulatory and Quality |
| Juan Lorenzo | Senior Vice President of Product Development |
| Mark Pomeranz | GM and Executive Vice President of Interventional Therapies |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 4, 2025 | 8-K | Current Report |
| Aug 1, 2025 | 424B5 | Filing |
| Jul 31, 2025 | 424B5 | Filing |
| Jul 31, 2025 | 8-K | Current Report |
| Jun 26, 2025 | 144 | Filing |
| Jun 24, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | SCHEDULE 13D/A | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |